These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15244083)

  • 1. Production of Carbopol 974P and Carbopol 971P pellets by extrusion-spheronization: optimization of the processing parameters and water content.
    Mezreb N; Charrueau C; Boy P; Allain P; Chaumeil JC
    Drug Dev Ind Pharm; 2004 May; 30(5):481-90. PubMed ID: 15244083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation and process considerations for beads containing Carbopol 974P, NF resin made by extrusion-spheronization.
    Neau SH; Chow MY; Hileman GA; Durrani MJ; Gheyas F; Evans BA
    Int J Pharm; 2000 Apr; 199(2):129-40. PubMed ID: 10802406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of process variables on physical properties of the pellets using extruder and spheronizer.
    Umprayn K; Chitropas P; Amarekajorn S
    Drug Dev Ind Pharm; 1999 Jan; 25(1):45-61. PubMed ID: 10028418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of к-carrageenan, chitosan and Carbopol 974P in extruded and spheronized pellets that are devoid of MCC.
    Valle BL; Omwancha WS; Neau SH; Wigent RJ
    Drug Dev Ind Pharm; 2016 Nov; 42(11):1903-16. PubMed ID: 27100683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of microcrystalline cellulose grade and process variables on pellets prepared by extrusion-spheronization.
    Alvarez L; Concheiro A; Gómez-Amoza JL; Souto C; Martínez-Pacheco R
    Drug Dev Ind Pharm; 2002 Apr; 28(4):451-6. PubMed ID: 12056538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation on the co-extrudability and spheronization properties of wet masses.
    Pinto JF; Lameiro MH; Martins P
    Int J Pharm; 2001 Oct; 227(1-2):71-80. PubMed ID: 11564542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrusion/spheronization--effect of moisture content and spheronization time on pellet characteristics.
    Iyer RM; Augsburger LL; Pope DG; Shah RD
    Pharm Dev Technol; 1996 Dec; 1(4):325-31. PubMed ID: 9552316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of extrusion aids for successful production of Kollidon
    Loka NC; Saripella KK; Pinto CA; Neau SH
    Drug Dev Ind Pharm; 2018 Apr; 44(4):632-642. PubMed ID: 29183166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucoadhesive platforms for targeted delivery to the colon.
    Varum FJ; Veiga F; Sousa JS; Basit AW
    Int J Pharm; 2011 Nov; 420(1):11-9. PubMed ID: 21856393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrusion-Spheronization of blends of carbopol 934 and microcrystalline cellulose.
    Gómez-Carracedo A; Alvarez-Lorenzo C; Gómez-Amoza JL; Martínez-Pacheco R; Souto C; Concheiro A
    Drug Dev Ind Pharm; 2001 May; 27(5):381-91. PubMed ID: 11448045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Quality by Experimental Design Approach to Assess the Effect of Formulation and Process Variables on the Extrusion and Spheronization of Drug-Loaded Pellets Containing Polyplasdone® XL-10.
    Saripella KK; Loka NC; Mallipeddi R; Rane AM; Neau SH
    AAPS PharmSciTech; 2016 Apr; 17(2):368-79. PubMed ID: 26169900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of particle kinematics in spheronization via particle image velocimetry.
    Koester M; Thommes M
    Eur J Pharm Biopharm; 2013 Feb; 83(2):307-14. PubMed ID: 23000404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing, optimisation & characterization of sustained release matrix pellets prepared by extrusion spheronization containing mixture of proteolytic enzymes.
    Chivate AA; Poddar SS
    Curr Drug Deliv; 2008 Oct; 5(4):265-74. PubMed ID: 18855595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of drug-containing spherical pellets produced by a hot-melt extrusion and spheronization process.
    Young CR; Koleng JJ; McGinity JW
    J Microencapsul; 2003; 20(5):613-25. PubMed ID: 12909545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical approaches to preparing pelletized dosage forms using the extrusion-spheronization process.
    Trivedi NR; Rajan MG; Johnson JR; Shukla AJ
    Crit Rev Ther Drug Carrier Syst; 2007; 24(1):1-40. PubMed ID: 17430098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and evaluation of omeprazole pellets fabricated by sieving-spheronization and extrusion - spheronization process.
    Karim S; Baie SH; Hay YK; Bukhari NI
    Pak J Pharm Sci; 2014 May; 27(3):425-38. PubMed ID: 24811797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of papain containing pellets produced by extrusion-spheronization: an operational stage approach.
    Varca GH; Lopes PS; Ferraz HG
    Drug Dev Ind Pharm; 2015 Mar; 41(3):430-5. PubMed ID: 24410044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and characterization of pellets using Avicel CL611 as spheronization aid.
    Puah SY; Yap HN; Chaw CS
    Drug Dev Ind Pharm; 2014 Mar; 40(3):418-24. PubMed ID: 23480532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colon targeted bioadhesive pellets of curcumin and cyclosporine for improved management of inflammatory bowel disease.
    Desai N; Momin M
    Drug Deliv Transl Res; 2020 Oct; 10(5):1288-1301. PubMed ID: 32277353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of fine particle ethylcellulose as the diluent in the production of pellets by extrusion-spheronization.
    Mallipeddi R; Saripella KK; Neau SH
    Saudi Pharm J; 2014 Sep; 22(4):360-72. PubMed ID: 25161381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.